These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12366465)

  • 21. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation.
    Raskin S; Katz G; Zislin Z; Knobler HY; Durst R
    Acta Psychiatr Scand; 2000 Apr; 101(4):334-6. PubMed ID: 10782556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Each of the following statements about the newer medications for schizophrenia, risperidone (risperidol) and clozapine (clozaril), is true, except: Patients receiving risperidone are at risk for agranulocytosis.
    Can Fam Physician; 1995 Oct; 41():1678, 1680. PubMed ID: 8829578
    [No Abstract]   [Full Text] [Related]  

  • 23. A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.
    Honer WG; Procyshyn RM; Chen EY; MacEwan GW; Barr AM
    J Psychiatry Neurosci; 2009 Nov; 34(6):433-42. PubMed ID: 19949719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clozapine resistance: augmentation strategies.
    Porcelli S; Balzarro B; Serretti A
    Eur Neuropsychopharmacol; 2012 Mar; 22(3):165-82. PubMed ID: 21906915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Augmenting atypical antipsychotic medications with clozapin].
    Zink M; Dressing H
    Nervenarzt; 2005 Sep; 76(9):1092, 1094-8, 1100-2. PubMed ID: 15782324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia.
    Mouaffak F; Tranulis C; Gourevitch R; Poirier MF; Douki S; Olié JP; Lôo H; Gourion D
    Clin Neuropharmacol; 2006; 29(1):28-33. PubMed ID: 16518132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clozapine alone versus clozapine and risperidone with refractory schizophrenia.
    Honer WG; Thornton AE; Chen EY; Chan RC; Wong JO; Bergmann A; Falkai P; Pomarol-Clotet E; McKenna PJ; Stip E; Williams R; MacEwan GW; Wasan K; Procyshyn R;
    N Engl J Med; 2006 Feb; 354(5):472-82. PubMed ID: 16452559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
    Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
    Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Augmentation strategies in patients with schizophrenia who show partial response to clozapine treatment].
    Vayısoğlu S; Anıl Yağcıoğlu E
    Turk Psikiyatri Derg; 2014; 25(3):201-11. PubMed ID: 25219694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.
    Ginsberg G; Shani S; Lev B
    Pharmacoeconomics; 1998 Feb; 13(2):231-41. PubMed ID: 10178649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When symptoms persist: clozapine augmentation strategies.
    Buckley P; Miller A; Olsen J; Garver D; Miller DD; Csernansky J
    Schizophr Bull; 2001; 27(4):615-28. PubMed ID: 11824488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials.
    Stahl SM
    J Clin Psychiatry; 1999; 60 Suppl 10():31-41. PubMed ID: 10340685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.